Contrast agent developer Nycomed of Oslo, Norway, has received a second approvable letter from the Food and Drug Administration for its Teslascan (mangafodipir trisodium) liver imaging agent for MRI studies. Teslascan had received an approvable letter
Contrast agent developer Nycomed of Oslo, Norway, has received a second approvable letter from the Food and Drug Administration for its Teslascan (mangafodipir trisodium) liver imaging agent for MRI studies. Teslascan had received an approvable letter last September, but the FDA raised additional questions about the agent's application that the company has been working to resolve (SCAN 10/9/96). With the second approvable letter now in hand, Nycomed expects final approval shortly, according to a spokesperson for the company's U.S. subsidiary in Princeton, NJ.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Stroke MRI Study Assesses Impact of Motion Artifacts Upon AI and Radiologist Lesion Detection
July 16th 2025Noting a 7.4 percent incidence of motion artifacts on brain MRI scans for suspected stroke patients, the authors of a new study found that motion artifacts can reduce radiologist and AI accuracy for detecting hemorrhagic lesions.